Total submissions: 13
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000656775 | SCV000149194 | uncertain significance | not provided | 2024-07-08 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Identified in individuals with a personal history of breast, colorectal, or other cancers (PMID: 31159747, 30613976, 33606809, 28944238, 26580448); This variant is associated with the following publications: (PMID: 26580448, 30613976, 28944238, 31937788, 33606809, 31159747) |
Eurofins Ntd Llc |
RCV000656775 | SCV000228762 | uncertain significance | not provided | 2015-04-24 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000460513 | SCV000543353 | benign | Bloom syndrome | 2024-01-31 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV000460513 | SCV000611375 | uncertain significance | Bloom syndrome | 2017-05-23 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV000574815 | SCV000672903 | likely benign | Hereditary cancer-predisposing syndrome | 2018-06-13 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Gene |
RCV000574815 | SCV000821900 | uncertain significance | Hereditary cancer-predisposing syndrome | 2018-08-01 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV000460513 | SCV001652747 | uncertain significance | Bloom syndrome | 2021-05-18 | criteria provided, single submitter | clinical testing | |
Institute for Clinical Genetics, |
RCV000656775 | SCV002010767 | uncertain significance | not provided | 2021-11-03 | criteria provided, single submitter | clinical testing | |
St. |
RCV000460513 | SCV002012383 | uncertain significance | Bloom syndrome | 2021-09-09 | criteria provided, single submitter | clinical testing | The BLM c.191A>T (p.Asp64Val) missense change has a maximum subpopulation frequency of 0.054% in gnomAD v2.1.1, including one homozygous occurrence (https://gnomad.broadinstitute.org/variant/15-91292689-A-T). It has also been identified in 2/1358 non-cancer control individuals in a study of individuals with multiple primary cancers (PMID: 29641532). Data submitted to ClinVar indicate that this variant has been seen in trans with a pathogenic variant or in the homozygous state in an individual without severe disease (ClinVar Accession: SCV000672903.3). In silico tools are not in agreement about the effect of this variant on protein function, but to our knowledge these predictions have not been confirmed by functional studies. To our knowledge, this variant has not been reported in individuals with Bloom syndrome. In summary, this variant meets criteria to be classified as of uncertain significance based on the ACMG/AMP criteria: no criteria applied. |
Quest Diagnostics Nichols Institute San Juan Capistrano | RCV000656775 | SCV002046949 | likely benign | not provided | 2023-07-11 | criteria provided, single submitter | clinical testing | |
Sema4, |
RCV000574815 | SCV002533669 | uncertain significance | Hereditary cancer-predisposing syndrome | 2022-03-03 | criteria provided, single submitter | curation | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV001800401 | SCV002548366 | uncertain significance | not specified | 2022-05-11 | criteria provided, single submitter | clinical testing | Variant summary: BLM c.191A>T (p.Asp64Val) results in a non-conservative amino acid change located in the Bloom syndrome protein, N-terminal domain (IPR032437) of the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.00024 in 250804 control chromosomes, predominantly at a frequency of 0.0005 within the Non-Finnish European subpopulation in the gnomAD database, including 1 homozygote. This frequency is not significantly higher than expected for a pathogenic variant in BLM causing Bloom Syndrome (0.00024 vs 0.0035), allowing no conclusion about variant significance. c.191A>T has been reported in the literature in individuals affected with autosomal dominant cancer-predisposition syndromes, breast and/or ovarian cancer (Zhang_2015, Rizzolo_2019, Tsaousis_2019, Sandoval_2021). These reports do not provide unequivocal conclusions about association of the variant with Bloom Syndrome. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Eleven ClinVar submitters (evaluation after 2014) cite the variant as uncertain significance (n=7), likely benign (n=3) and benign (n=1). Based on the evidence outlined above, the variant was classified as uncertain significance. |
Natera, |
RCV000460513 | SCV001456976 | benign | Bloom syndrome | 2019-08-06 | no assertion criteria provided | clinical testing |